Tags:CommerceDiagnosticsFastHealthIndustryInformationMarketMarketingMedicalMedTechPersonalPlatformRealTime
Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.* Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com * http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market
Likes
1209
Member count: 501-1000
Total raised: $267.16721M

Investors 2

Funding Rounds 5

DateSeriesAmountInvestorsDeal News
11.05.2021Grant$1.703581M--
05.09.2014-$83.53905M--
06.11.2013Series E$40.545252...--
12.12.2012Series D$45.628764...--
17.11.2011Series C$95.750563...--

Mentions in press and media 41

DateTitleDescriptionCategoryAuthorSource
10.11.2021Press rele...PRESS RELEASE: REGULATED INFOR...--marketscre...
02.11.2021Intervest ...Biocartis, located in the Inte...--marketscre...
12.10.2021Biocartis ...PRESS RELEASE REGULATED INFOR...--marketscre...
23.09.2021Biocartis ...PRESS RELEASE 23 September 20...--marketscre...
13.09.2021Biocartis ...PRESS RELEASE REGULATED INFOR...--marketscre...
02.09.2021Biocartis ...PRESS RELEASE 2 September 202...--marketscre...
02.09.2021Biocartis ...PRESS RELEASE REGULATED INFOR...--marketscre...
30.08.2021Biocartis ...PRESS RELEASE REGULATED INFOR...--marketscre...
26.08.2021BIOCARTIS ...PRESS RELEASE REGULATED INFOR...--marketscre...
02.08.2021Biocartis ...PRESS RELEASE 2 August 2021, ...--marketscre...
Show more